Opinion|Videos|February 7, 2025
Discontinuing Versus Switching BTK Inhibitors for Toxicity
Panelists discuss how data from Mansour and colleagues suggesting potential Bruton tyrosine kinase (BTK) inhibitor discontinuation after 2+ years of therapy opens up new treatment strategy considerations, with decisions between discontinuation vs switching to alternative BTK inhibitor (BTKi) therapy being influenced by factors such as depth and duration of response, toxicity severity, patient preferences regarding adverse effects and treatment schedules, and quality-of-life considerations.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- The ASH abstract by Mansour and colleagues suggests that for patients who have been on BTK inhibitors for more than 2 years, discontinuing therapy and observing the patient off-treatment might be an option, rather than switching to another BTKi immediately. What is your interpretation of this approach, and what factors would influence your decision to discontinue BTKi therapy due to toxicity instead of switching to an alternative BTKi?
- How should patient preferences regarding adverse effects, treatment schedules, and efficacy trade-offs influence the decision to switch or continue BTKi therapy?
- Consider reviewing the abstract by Ailawadhi and colleagues on patient preferences for BTKi.
Advertisement
Related to this article
Michael Mina, MD, PhD, explains which adverse events drove VYD2311's edge vs an mRNA COVID-19 vaccine and who may benefit most.
Biomarker-driven care is advancing in mantle cell lymphoma, though cost and infrastructure limit access in community oncology, according to a review.
Fibrosis stage, not MASH resolution, best predicts mortality, which should shape trial end points, says Georgetown's Zobair Younossi, MD, MPH.
Remibrutinib (Rhapsido; Novartis) is the only treatment with approved uses in both chronic spontaneous urticaria and symptomatic dermographism.
Lean MASLD shows milder histology than overweight and obese MASLD but similar mortality and event risk, with fibrosis tied to prognosis.
Hepatitis reports after vaccination were more often serious in children, but the data lack dose counts and cannot show vaccine-specific risk.
The Autus Size-Adjustable Valve, which can be expanded as children grow, may reduce the need for repeat open-heart surgeries for congenital defects.
Phase 3 wins for ianalumab and dazodalibep bring targeted therapies closer for Sjögren disease as patients face diagnostic delays and high costs.
Advertisement
Advertisement
Trending on AJMC
1
Predoc and Nebraska Cancer Specialists: Not Letting the Fax Be the Fumble
2
Postvaccine Hepatitis Reports More Often Serious in Children vs Adults
3
CMS Moves TIC Reporting to Quarterly, Sets Drug File Timeline
4
Up to 400 mg of Caffeine Daily Is Safe for Most Adults, AHA Says
5